Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic disease.
Genespire's focus is particularly primary immunodeficiencies and inherited metabolic diseases.
Genespire was founded in March 2020 as a spin-off of the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) co-founded by Fondazione Telethon and the San Raffaele Hospital, along with Prof. Naldini and Dr. Alessio Cantore. The company is headquartered in Milano, Italy.
Genespire has raised €16M in a Series A round on April 29, 2020. The financing was led by Sofinnova Partners.